SG&A Efficiency Analysis: Comparing Alpine Immune Sciences, Inc. and Ultragenyx Pharmaceutical Inc.

Biotech Giants: A Decade of SG&A Expense Trends

__timestampAlpine Immune Sciences, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 2014228770910811000
Thursday, January 1, 2015684400033001000
Friday, January 1, 2016858600064936000
Sunday, January 1, 2017607900099909000
Monday, January 1, 20188362000127724000
Tuesday, January 1, 20199467000161524000
Wednesday, January 1, 202010899000182933000
Friday, January 1, 202114560000219982000
Saturday, January 1, 202217968000278139000
Sunday, January 1, 202322222000309799000
Loading chart...

Unveiling the hidden dimensions of data

SG&A Efficiency: A Tale of Two Biotech Innovators

In the competitive world of biotechnology, managing operational expenses is crucial for sustainable growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Alpine Immune Sciences, Inc. and Ultragenyx Pharmaceutical Inc. over a decade, from 2014 to 2023.

Alpine Immune Sciences, Inc. has shown a steady increase in SG&A expenses, growing nearly tenfold from 2014 to 2023. In contrast, Ultragenyx Pharmaceutical Inc. has experienced a more dramatic rise, with expenses increasing by approximately 2,800% over the same period. By 2023, Ultragenyx's SG&A expenses were about 14 times higher than Alpine's, highlighting its aggressive expansion strategy.

This data underscores the differing approaches of these companies in managing operational costs, with Ultragenyx investing heavily in growth and Alpine maintaining a more conservative expenditure strategy.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025